Replies to post #184655 on Elite Pharmaceuticals Inc (ELTP)

[Je3232]

I agree and that's all I'm saying. As the business grows and the level of complexity grows, it might be time to cut loose from the past. Finance and IR are weak in my opinion. Again, just my opinion. Loyalty is nice but it doesn't pay the rent or help shareholders. One big miss on the books in the future and this stock tanks. Again - just my opinion.

[Couch]

Yeah would be nice if that were true but its not. Carter, the CFO, in no way shape or form screwed up. But hey if you actually have proof beyond BS speculation the board would love to see it. Accounting 101 says show the math.

Starting with the P&L statement. Our revenues for the quarter were $2.2 million, approximately $2 million of that came from our generic operations and $250,000 from amortization of the $5 million license fee received from that for SequestOx. That’s a 61% year-on-year increase in revenues. Revenues for the first nine months of the fiscal year from April through December was $7.3 million. That number, that nine month number is almost 50% higher than the $5 million in revenues that we recorded for the entire 12 months of last year. Again this is almost entirely due to the growth in our generic products which continue to perform well as they mature in the market. The financials clear show this growth is being sustained and all data and forecasts that we have give no reason to conclude otherwise when looking forward as well.